Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

Abstract: The present specification discloses compositions comprising a plurality of therapeutic compound having antitussive activity and methods and uses for treating a coughing condition with such compositions.

Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a cardiovascular disease in an individual using such pharmaceutical compositions.

Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

Abstract: The present specification discloses compositions comprising a plurality of therapeutic compound having antitussive activity and methods and uses for treating a coughing condition with such compositions.

Abstract: The present specification discloses compositions comprising a plurality of therapeutic compound having antitussive activity and methods and uses for treating a coughing condition with such compositions.

Abstract: The present specification discloses compositions comprising a plurality of therapeutic compound having antitussive activity and methods and uses for treating a coughing condition with such compositions.

Abstract: The present specification discloses compositions comprising a pharmaceutical composition to reduce or maintain LDL and/or cholesterol levels in an individual and a plurality of therapeutic compounds to increase or maintain HDL levels in an individual. The present specification also discloses a treatment protocol wherein a pharmaceutical composition is administered to an individual on a schedule wherein the pharmaceutical composition is provided for a period of time and then not provided to the individual and this treatment protocol is repeated for the term of the individual's treatment.

Abstract: The present invention is theobromine as an active agent to be delivered via the inhaled route, for the treatment of cough.

Abstract: The invention provides compositions, medicaments and methods of treating microbial infections, and especially respiratory disorders caused by microbial infections. In particular, the invention relates to the treatment of respiratory diseases caused by pathogenic infections using certain either alkyl substituted or un-substituted 2-aryl acetic acid, or 2-aryl, N-hydroxyacetamide derivatives, or pentoxifylline, and to the use of these compounds in methods of treatment.

Abstract: This invention relates to the treatment of respiratory disorders, and in particular respiratory disorders and oedema caused by pathogenic infections. In particular, the invention relates to orally administrable pharmaceutical compositions for treating respiratory disorders, and to methods of such treatment. The invention is particularly concerned with the treatment of respiratory disorders that are caused by viral infections, such as with influenza viral strains. The invention also extends to analgesic compositions and methods for treating inflammatory pain manifesting in a variety of diseases, and not only respiratory diseases.

Abstract: The invention provides compositions, medicaments and methods of treatment of viral infections, especially respiratory disorders caused by viral infections. In particular, the invention relates to the treatment of acute viral infections using a range of related 1-phenyl-2-amino ethanol, ethanal, and ethane derivatives.

Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a cardiovascular disease in an individual using such pharmaceutical compositions.

Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

Abstract: The present specification discloses beta-amino alcohols and methods of treating a neurodegenerative disease using such compounds.

Abstract: The present specification discloses compositions comprising a plurality of therapeutic compound having antitussive activity and methods and uses for treating a coughing condition with such compositions.

Abstract: A compound for therapeutic use, of the formula wherein R1 is aryl or heteroaryl optionally substituted with R5; R2 is H, alkyl or CH2OH or forms part of a ring with R4; R3 is H, alkyl or CH2OH or forms part of a ring with R4; R4 is H, alkyl or (when forming part of a ring with R2 or R3) CH2; and R5 is alkyl, CF3, OH, Oalkyl, OCOalkyl, CONH2, CN, halogen, NH2, NO2, NHCHO, NHCONH2, NHSO2Me, CONH2, or SOMe; or a salt thereof.

Abstract: Use of a compound for the manufacture of a medicament for use in therapy of a neurodegenerative condition, wherein the compound is of formula (I): wherein R1 is CHR4—OR5 or CHR4—SR5, or aryl or heteroaryi optionally substituted with one or more groups R6; R2 is alkyl or is part of a ring with R3; R3 is H, alkyl or CH2 (when forming part of a ring with R2); R4 is H or alkyl or is part of a ring with R 5; R5 is aryl or heteroaryi optionally substituted with R7; each R6 is independently alkyl, CF3, OH, Oalkyl, OCOalkyl, CONH2, CN, halogen, NH2, NO2, NHCHO, NHCONH2, NHSO2alkyl, CONH2, SOMe, SO2NH2, Salkyl, CH2SO2alkyl or OCONalkyl2; R7 is R8 or (CH2)nOR8, R9, CF3, OH, OR9, OCOR9, COR9, COOR9, CONH2, CH2CONH2, CN, halogen, NH2, NO2, NHCHO, NHCONH2, NHCONHR7, NHCON(R9)2, NHCOR9, NHCOaryl, NHSO2Me, CONH2, SMe, SOMe or SO2NH2; R8 is (CH2)nOR9, (CH)nOR9, (CH2)nCOOR9 or (CH2)nCOaryl; R9 is alkyl or cycloalkyl; and n is 1 to 4; or a salt thereof.

Abstract: A compound for therapeutic use, of the formula (I), wherein R1 is aryl or heteroaryl optionally substituted with R5; R2 is H, alkyl or CH2OH or forms part of a ring with R4; R3 is H, alkyl or CH2OH or forms part of a ring with R4; R4 is H, alkyl or (when forming part of a ring with R2 or R3) CH2; and R5 is alkyl, CF3, OH, Oalkyl, OCOalkyl, CONH2, CN, halogen, NH2, NO2, NHCHO, NHCONH2, NHSO2Me, CONH2, or SOMe; or a salt thereof.

Abstract: An agent, which is amlexanox, is useful in the therapy of a disease associated with neutrophilia.